The medical healthcare specialist company METAROBOTICS continued to achieve strong performance in the first half of this year.
On the 15th, METAROBOTICS announced that it recorded consolidated revenue of 76 billion won and operating profit of 10.8 billion won in the first half of this year. Revenue and operating profit both increased by 32% and 37%, respectively, compared to the same period last year.
METAPHARM drove the strong performance. With the support of its subsidiary EZEN IMPLANT, it recorded a 86% increase in revenue and a 133% increase in operating profit compared to the same period last year, achieving the highest revenue for a half-year and maintaining profitability for 17 consecutive quarters.
A representative from METAROBOTICS said, "We will continue our growth momentum by accelerating METAPHARM's global expansion and enhancing the platform of TECHLABS, and we plan to make a full-scale entry into the AI medical robotics business to strengthen our growth base."